AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer.
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Axogen: Well Placed To Capitalize Growth At Higher Multiples
Axogen: Well Placed To Capitalize Growth At Higher Multiples
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%
The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript
Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer.
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
